Long-term benefit of high-density lipoprotein cholesterol-raising therapy with Bezafibrate 16-Year mortality follow-up of the Bezafibrate infarction prevention trial

Archives of Internal Medicine

Volumn 169, Issue 5, 2009, Pages 508-514

  Goldenberg, Ilan ^a,b   Boyko, Valentina ^b   Tennenbaum, Alexander ^c   Tanne, David ^d   Behar, Solomon ^a,b,d   Guetta, Victor ^a  

^a Heart Institute Neufeld   (Israel)

^b Cardiac Rehabilitation Institute   (Israel)

^c Stroke Unit   (Italy)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL TIME;

AGED; ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLESTEROL, HDL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 62349105940     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2008.584     Document Type: Article

References (26)

1. Drexel H. Reducing risk by raising HDL-cholesterol: the evidence. Eur Heart J. 2006;8(supp! F):F23-F29.
2. Brown BG, Zhao XQ, Crtait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22)1583-1592.
3. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256(20):2835-2838.
4. Sacks FM, Tonkin AM, Craven T, et at Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002:105(12):1424-1428.
5. Olsson AG, Lang PD, Vollmar J. Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia. Atherosclerosis. 1985:55(2):195-203.
6. Frick MH, Elo 0, Haapa K, et al Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317(20)1237-1245.
7. Rubins HB, Robins SJ, Collins D, et al; Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341 (8) :410-418.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
9. Bruckert E, Baccara-Dinet M, McCoy F, Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin. 2005;21 (12):1927-1934.
10. Goldbourt U, Behar S, Reicher-Reiss H, et al. for Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinical manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial), Am J Cardiol. 1993:71 (11):909-915.
11. The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21-27.
12. Goldenberg I, Goldbourt U, Boyco V, Behar S, Reicher-Reiss H, Relationship between on-treatment increments in serum HDL levels and cardiac events in patients with coronary heart disease: an extended follow-up of the Bezafibrate Infarction Prevention trial. Am J Cardiol. 2006;97(4):466-471.
13. Goldenberg I, Benderly M, Goldbourt U; BIP Study Group. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial, J Am Coll Cardiol. 2008;51 (4)459-465.
14. SAS Institute Inc. SAS/STAT Software: Changes and Enhancement Through Release 6.11. Gary, NC: SAS Institute Inc; 1996:813.
15. Ischaemic heart disease: a secondary prevention trial using clofibrate: report by a esearch committee of the Scottish Society of Physicians. Br Med J. 1971;4(5790):775-784.
16. Trial of clofibrate in the treatment of ischaemic heart disease: five-year study by a group of physicians of the Newcastle Upon Tyne region. Br Med J. 1971; 4(5790):767-775.
17. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators. Br Heart J. 1978; 40(10)1069-1118.
18. WHO cooperative trial on primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol: final mortality follow-up: report of the Committee of Principal Investigators. Lancet. 1984;2(8403):600- 604.
19. Tenkanen L, Manttari M, Kovanen P, Virkkunnen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med. 2006;166(7):743-748.
20. Canner PL, Berge KG, Wenger NK, et al Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-1255.
21. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260(5):641-651.
22. Robins SJ, Collins D, Wittes JT, et al; VA-HIT Study Group. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001:285(12) 1585-1591.
23. Tenenbaum A, Motro M, Fisman E, et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with the metabolic syndrome. Arch Intem Med. 2005;165(10)1154-1160.
24. Keech A, Simes RJ, Barter PB, et al; FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500)1849-1861.
25. Barter P, Gotto AM, LaRosa JC, et al; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007:357(13):1301-1310.
26. deGomaEM, Leeper NJ, Heidenreich PA, Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51(1):49-55.